Dynamics of CD4⁺ T-Cells and Neutralizing Antibody Responses to Three Consecutive Doses of Inactivated COVID-19 Vaccines in PLWH

References

• Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154.
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica. 2020;91(1):157–160. doi:10.23750/abm.v91i1.9397
   Google Scholar
• Abdelmaksoud A, Wollina U, Temiz SA, Hasan A. SARS-CoV-2 vaccination-induced cutaneous vasculitis: report of two new cases and literature review. Dermatol Ther. 2022;35(6):e15458. doi:10.1111/dth.15458
   PubMed Web of Science ®Google Scholar
• Dotiwala F, Upadhyay AK. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. Front Immunol. 2022;13:940715. doi:10.3389/fimmu.2022.940715
   PubMed Web of Science ®Google Scholar
• Bert F, Pivi A, Russotto A, et al. COVID-19 vaccination among HIV+ patients: an Italian cross-sectional survey. Vaccines. 2022;10:9. doi:10.3390/vaccines10091438
   Google Scholar
• British HIV Association. Comment from BHIVA and THT on UK Government guidance on coronavirus (COVID-19), social distancing to protect vulnerable adults and shielding to protect extremely vulnerable adults; 2020. Available from: https://www.bhiva.org/comment-from-BHIVA-and-THT-on-UK-Government-guidance-on-Coronavirus-COVID-19. Accessed April 27, 2023.
   Google Scholar
• Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021;27(7):1147–1148. doi:10.1038/s41591-021-01432-4
   PubMed Web of Science ®Google Scholar
• Dapporto F, Marchi S, Leonardi M, et al. Antibody avidity and neutralizing response against SARS-CoV-2 omicron variant after infection or vaccination. J Immunol Res. 2022;2022:4813199. doi:10.1155/2022/4813199
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhang Y, He Z, et al. Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study. EClinicalMedicine. 2022;43:101226. doi:10.1016/j.eclinm.2021.101226
   PubMedGoogle Scholar
• Vergori A, Cozzi Lepri A, Cicalini S, et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nat Commun. 2022;13(1):4922. doi:10.1038/s41467-022-32263-7
   PubMed Web of Science ®Google Scholar
• Painter MM, Mathew D, Goel RR, et al. Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54(9):2133–2142 e3. doi:10.1016/j.immuni.2021.08.001
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng J, Islam MS, Yang Y, Hu Y, Chen X. The role of CD4(+)FoxP3(+) regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment. Int J Biol Sci. 2021;17(6):1507–1520. doi:10.7150/ijbs.59534
   PubMed Web of Science ®Google Scholar
• Uraki R, Imai M, Ito M, et al. Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. PLoS Pathog. 2021;17(12):e1010085. doi:10.1371/journal.ppat.1010085
   PubMed Web of Science ®Google Scholar
• Huang WT, Weng SW, Tzeng HT, Yen FC, Chiang YS, You HL. Lymphocyte subpopulations associated with neutralizing antibody levels of SARS-CoV-2 for COVID-19 vaccination. Vaccines. 2022;10(9):1550. doi:10.3390/vaccines10091550
   Web of Science ®Google Scholar
• Faissner S, Heitmann N, Plaza-Sirvent C, et al. Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination. Front Immunol. 2022;13:980526. doi:10.3389/fimmu.2022.980526
   PubMed Web of Science ®Google Scholar
• Yao Y, Wang ZZ, Huang A, et al. TFH 2 cells associate with enhanced humoral immunity to SARS-CoV-2 inactivated vaccine in patients with allergic rhinitis. Clin Transl Med. 2022;12(1):e717. doi:10.1002/ctm2.717
   PubMed Web of Science ®Google Scholar
• National Medical Products Administrations. NMPA issued the guidelines for adverse event classification standards for clinical trials of preventive vaccines; 2019. Available from: https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20191231111901460.html. Accessed December 26, 2019.
   Google Scholar
• Kaneko Y, Sugiyama A, Tanaka T, et al. The serological diversity of serum IgG/IgA/IgM against SARS-CoV-2 nucleoprotein, spike, and receptor-binding domain and neutralizing antibodies in patients with COVID-19 in Japan. Health Sci Rep. 2022;5(3):e572. doi:10.1002/hsr2.572
   PubMedGoogle Scholar
• Zhang J, Xing S, Liang D, et al. Differential antibody response to inactivated COVID-19 vaccines in healthy subjects. Front Cell Infect Microbiol. 2021;16(11):791660. doi:10.3389/fcimb.2021.791660
   Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501. doi:10.1016/j.cell.2020.05.015
   PubMed Web of Science ®Google Scholar
• Bai J, Chiba A, Murayama G, Kuga T, Tamura N, Miyake S. Sex, age, and ethnic background shape adaptive immune responses induced by the SARS-CoV-2 mRNA vaccine. Front Immunol. 2022;13:786586. doi:10.3389/fimmu.2022.786586
   PubMed Web of Science ®Google Scholar
• Han X, Yu X, Han Y, et al. Safety and immunogenicity of inactivated COVID-19 vaccines among people living with HIV in China. Infect Drug Resist. 2022;15:2091–2100. doi:10.2147/IDR.S353127
   PubMed Web of Science ®Google Scholar
• Cai S, Liao G, Yu T, et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: a cross-sectional study. J Med Virol. 2022;94(9):4224–4233. doi:10.1002/jmv.27872
   PubMed Web of Science ®Google Scholar
• Zou S, Guo W, Wu S, et al. Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIV. Front Immunol. 2022;13:988304. doi:10.3389/fimmu.2022.988304
   PubMedGoogle Scholar
• Huang X, Yan Y, Su B, et al. Comparing immune responses to inactivated vaccines against SARS-CoV-2 between people living with HIV and HIV-negative individuals: a cross-sectional study in China. Viruses. 2022;14(2):277. doi:10.3390/v14020277
   PubMed Web of Science ®Google Scholar
• Yin J, Chen Y, Li Y, Wang C, Zhang X. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. Int J Infect Dis. 2022;124:212–223. doi:10.1016/j.ijid.2022.10.005
   PubMed Web of Science ®Google Scholar
• Antinori A, Cicalini S, Meschi S, et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-lymphocyte count. Clin Infect Dis. 2022;75(1):e552–e563. doi:10.1093/cid/ciac238
   PubMed Web of Science ®Google Scholar
• Rydyznski Moderbacher C, Kim C, Mateus J, et al. NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses. J Clin Invest. 2022;132(19):e160898. doi:10.1172/JCI160898
   PubMed Web of Science ®Google Scholar